Sugi Predict

Sugi Predict / Compounds / SCHEMBL1193310

SCHEMBL1193310

SCHEMBL1193310

Clc1cc2[nH]cnc2cc1N1CCCC1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.47
▸ IP6K1 Q92551 7/20 0.47
▸ EGLN1 Q9GZT9 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ APEX1 P27695 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ IP6K3 Q96PC2 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ TYMS P04818 1/20 0.38
▸ ALDH1A3 P47895 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL352396 0.74 MAPT (0.70) MAPTALDH1A1KDM4EAPEX1RECQL
SCHEMBL1193159 0.73 EGLN1 (0.44) MAPTIP6K1EGLN1ALDH1A1KDM4E
Hydrochloric Acid SCHEMBL22748994 0.73 MAPT (0.68) MAPTALDH1A1KDM4EAPEX1RECQL
SCHEMBL2317063 0.72 MAPT (0.61) MAPTALDH1A1KDM4EAPEX1RECQL
SCHEMBL30390007 0.72 MAPT (0.61) MAPTALDH1A1KDM4EAPEX1RECQL
SCHEMBL1444275 0.70 IP6K1 (0.59) MAPTIP6K1ALDH1A1KDM4EPOLB
SCHEMBL23122450 0.69 IP6K1 (0.60) MAPTIP6K1ALDH1A1KDM4ETDP1
SCHEMBL20089105 0.69 IP6K1 (0.57) MAPTIP6K1ALDH1A1KDM4EAPEX1
SCHEMBL27517100 0.69 IP6K1 (0.64) MAPTIP6K1ALDH1A1KDM4EPOLB
SCHEMBL30089756 0.68 MAPT (0.56) MAPTALDH1A1KDM4EAPEX1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2023-04-04 — — US disclosed
US-20210078978-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-03-18 — — US disclosed
US-10851083-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2020-12-01 — — US disclosed
US-20180215732-A9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-08-02 — — US disclosed
US-20180022733-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-01-25 — — US disclosed
US-20160168127-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2016-06-16 — — US disclosed
CN-105622580-A Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV 2016-06-01 — — CN disclosed
US-9073923-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-07-07 — — US disclosed
EP-2294066-B9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-03-11 — — EP disclosed
US-8865713-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-10-21 — — US disclosed
US-20140256722-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-11 — — US disclosed
EP-2294066-B1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-08-13 — — EP disclosed
US-8759345-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 — — US disclosed
US-20140005193-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (US) 2014-01-02 — — US disclosed
US-20110046132-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors P4HA1, PAH, EGLN3 MAPT 2583/4885IP6K1 3217/4885EGLN1 8/4885
US-20110046132-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2687/4885IP6K1 3342/4885EGLN1 10/4885
US-20180022733-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2583/4885IP6K1 3217/4885EGLN1 8/4885
US-20140005193-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2583/4885IP6K1 3217/4885EGLN1 8/4885
US-10851083-B2 Benzoimidazoles as prolyl hydroxylase inhibitors P4HA1, PAH, EGLN3 MAPT 2583/4885IP6K1 3217/4885EGLN1 8/4885
US-20180215732-A9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2583/4885IP6K1 3217/4885EGLN1 8/4885
US-20140256722-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2583/4885IP6K1 3217/4885EGLN1 8/4885
US-20210078978-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2583/4885IP6K1 3217/4885EGLN1 8/4885
US-20160168127-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 MAPT 2583/4885IP6K1 3217/4885EGLN1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.